Uso do peptídeo sintético Lys-a1 no favorecimento da atividade antimicrobiana de ciprofloxacina contra Pseudomonas aeruginosa ATCC 9027

Abstract

Most microorganism lies embedded in communities called "biofilms". Among these stand out Pseudomonas aeruginosa, an opportunistic pathogen of plants, animals and humans, frequently associated with nosocomial infections difficult to be eradicated due to the presence of biofilm. The fluoroquinolone antibiotics such as ciprofloxacin (CIP) against this bacterium are used, however, the mechanism of resistance has been developed for this microorganism. Thus, new forms of microbial control have been the subject of numerous studies in order to replace or enhance conventional methods. For this purpose, antimicrobial peptides (AMPs) obtained from various living beings represent an alternative to the development of new drugs. Synthetic forms analogous to Hylin a1 AMP (Hy-a1), isolated from species Hypsiboas albopunctatus, has shown excellent antimicrobial efficacy, among which stand out the peptide Lys-[Trp6]hy-a1 (Lys-a1). Thus, the aim of this work was to verify the influence of the peptide Lys-a1 in antimicrobial activity of CIP against pathogenic microorganism Pseudomonas aeruginosa ATCC 9027. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and the curve death were determined to CIP and Lys-a1 separately. The influence of Lys-a1 in the antimicrobial activity of the CIP has been verified by the checkerboard method to quantify the biomass and the number of viable cells in biofilms by crystal violet staining and counting of colony forming units (CFU), respectively. The MIC and MBC values of Lys-a1 was 125 μg.mL-1 and the CIP was 0.24 and 0.48 μg.mL-1, respectively. The data showed that both the CIP as Lys-a1 are potent antibiotics against P. aeruginosa is able to inhibit both the planktonic growth and biofilm development. The interaction of substances interpreted by the fractional inhibitory concentration index (FICI) and showed an additive effect, establishing a decrease of 16 times the MIC and MBC of the CIP, when combined with the Lys-a1. This effect was also observed in the kinetics of death and antibiofilm activity. In conclusion, the additive effect of the Lys-a1 and CIP in antimicrobial activity suggests that the peptide has potential as a therapeutic agent and an adjuvant for the treatment of infectious diseases caused by P. aeruginosa can enable the use of lower concentrations of the antibiotic.